Welcome to the New Mexico Chapter of the American College of Cardiology
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- New Studies Add to Evidence Involving Optimal Treatment of Patients Post-Ischemic StrokeTreatment of patients following ischemic stroke was the focus of three separate studies published in JAMA, two of which involved use of intravenous tenecteplase and the other involving thrombectomy plus intra-arterial alteplase.
- No Child Left Behind: The Case For Early Lipid ScreeningAtherosclerotic cardiovascular disease (ASCVD) is traditionally recognized as a disease of midadulthood. However, atherogenesis begins in childhood. Subclinical atherosclerosis can be detected as early as 8-10 years of age.
- JACC Spotlight Issue Provides Expert Insight on 2026 Dyslipidemia GuidelineA special JACC Spotlight Issue supporting the recently published 2026 ACC/AHA Guideline on the Management of Dyslipidemia, offers commentaries that provide a comprehensive overview of the new guideline recommendations and expert insights into understanding the science behind the recommendations...
- FDA Update: Agency Approves Baxdrostat to Treat Adults With HTNThe U.S. Food and Drug Administration (FDA) has approved baxdrostat, a first-in-class oral aldosterone synthase inhibitor, as an add-on therapy for hypertension in adults whose blood pressure (BP) is not adequately controlled with other antihypertensive medications.
- SURMOUNT-MAINTAIN: Continuing Tirzepatide Maintains Weight LossIn patients with obesity, continuing tirzepatide at either the maximum tolerated dose (MTD) of 10 or 15 mg or a reduced dose of 5 mg was safe and effectively maintained weight loss along with its associated health benefits, compared to switching to placebo, according to results from the SURMOUNT-MAINTAIN trial published May 12 in The […]